Novo Carves Deeper Niche Into CV Market With Staten Dyslipidemia Investment

 
• By Jo Shorthouse

Novo Nordisk is making good on its strategy to prioritize the cardiovascular sector. Its latest deal sees the Danish pharma invest in Staten Biotechnology’s hypertriglyceridemia asset, with potential to acquire the company.

SC1812_Carpenter_300751568_1200.jpg
Novo gets to grips with cardiovascular • Source: Shutterstock

More from Cardiovascular

More from Therapy Areas